It has been a few months now since the re-introductions of Tysabri (natalizumab) back into the U.S. market. The passion with which many MS patients urged the FDA's panel making the decision was unprecedented. Powerful to the point that, for only the second time in the agency's history, a drug pulled for safety concerns was allowed for continued use.
The MS community, doctors and even the stock market annalists were excited to have this powerful new drug once again allowed. The rules implemented by the FDA for use of Tysabri were also unprecedented in drug history.
The, so called, ?TOUCH? system requires doctors and infusions centers to be registered before they can prescribe or administer the drug. Patients must also register and comply with a mild set of guidelines which seem, if annoying, to be benign.
I have heard from doctors, nurse practitioners, nurses and drug reps on the topic, now I'd like to hear from patients - you know?the ones who really matter.
It is an expensive drug (I'm hearing as much as $5,500 per dose), and it has had its issues. The thing is, I have heard from people on the drug during Phase III trials that it also works (and works very well for many). See my earlier posting on this subject.
We know that your comments can only be what the professionals call, ?anecdotal evidence.? We're all okay with that. Many of us are or have thought about using the treatment. We want to know?
